8VP1 Stock Chart & Stats
€0.03
>-€0.01(-7.41%)
At close: 4:00 PM EDT
€0.03
>-€0.01(-7.41%)
Day’s Range― - ―
52-Week Range€0.02 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)2.67K
Market Cap
€4.04M
Enterprise Value€5.89M
Total Cash (Recent Filing)€922.55K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding126,369,670
10 Day Avg. Volume0
30 Day Avg. Volume2,670
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)13.00
Price to Sales (P/S)9.49
P/FCF Ratio-5.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetEssentially no debt reduces refinancing exposure, interest expense, and the risk that creditors constrain strategic choices. This gives Avricore greater flexibility to direct available resources toward HealthTab adoption and operating improvements, although it does not offset current losses.
Prior Gross-profit CapabilityPositive gross profit and improved margins in 2023–2024 show that the operating model has previously demonstrated underlying monetization potential. Re-establishing those economics would improve the durability of revenue growth and reduce dependence on external funding over time.
Integrated Pharmacy POCT PlatformHealthTab combines point-of-care testing, result management, and pharmacy workflow integration in one platform. A broader operating role within community pharmacies can support ongoing site usage and test-program expansion as participating locations and supported services increase.
Bears Say
Severe Revenue DeteriorationThe sharp decline from stronger 2023–2024 revenue levels indicates substantial top-line volatility and weak recent commercial execution. Persistently low revenue can limit operating leverage, reduce investment capacity, and make it harder for the platform to absorb fixed costs as the business scales.
Negative ProfitabilityNegative gross profit means current revenue does not cover direct costs, while widening operating and net losses signal that scale has not yet produced sustainable earnings. Continued underperformance could weaken the equity base and constrain resources available for product and market expansion.
Cash ConsumptionNegative operating and free cash flow show that the company is currently consuming cash rather than funding operations internally. If this persists, Avricore may have less flexibility to invest in HealthTab growth and face greater dependence on future financing to sustain operations.
Avricore Health News
8VP1 FAQ
What was Avricore Health Inc.’s price range in the past 12 months?
Avricore Health Inc. lowest stock price was €0.02 and its highest was €0.05 in the past 12 months.
What is Avricore Health Inc.’s market cap?
Avricore Health Inc.’s market cap is €4.04M.
When is Avricore Health Inc.’s upcoming earnings report date?
Avricore Health Inc.’s upcoming earnings report date is Nov 26, 2026 which is in 27 days.
How were Avricore Health Inc.’s earnings last quarter?
Avricore Health Inc. released its earnings results on Sep 01, 2026. The company reported -€0.002 earnings per share for the quarter.
Is Avricore Health Inc. overvalued?
According to Wall Street analysts Avricore Health Inc.’s price is currently Overvalued.
Does Avricore Health Inc. pay dividends?
Avricore Health Inc. does not currently pay dividends.
What is Avricore Health Inc.’s EPS estimate?
Avricore Health Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avricore Health Inc. have?
Avricore Health Inc. has 126,369,670 shares outstanding.
What happened to Avricore Health Inc.’s price movement after its last earnings report?
Avricore Health Inc. reported an EPS of -€0.002 in its last earnings report. Following the earnings report the stock price went down -32%.
Which hedge fund is a major shareholder of Avricore Health Inc.?
Currently, no hedge funds are holding shares in DE:8VP1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Avricore Health Inc.
Avricore Health Inc. operates within Canada, specializing in health data management and point-of-care technological solutions. Their primary offering is HealthTab, a precise, laboratory-quality diagnostic testing system designed for use in pharmacies. This enterprise maintains key alliances with prominent organizations such as Shoppers Drug Marts and Abbott. Established in 1996 and headquartered in Vancouver, Canada, the company previously operated as Vanc Pharmaceuticals Inc., adopting its current name, Avricore Health Inc., in October 2018.
Technical Analysis
BioMark Diagnostics
―
Telo Genomics Corp
―
StageZero Life Sciences Ltd
―
―
PanGenomic Health, Inc. Class A
―